Latest research on Xarelto

Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.

Latest findings

Half of the 102 patients included received rivaroxaban (Xarelto from Bayer) and half of them received apixaban (Eliquis; Bristol-Myers Squibb). [source, 2015]
Patient was discharged home on oral Xarelto (rivaroxaban) and compression stockings. [source, 2015]
In 2009, a new drug became available for the preventive treatment of thrombosis: the direct factor Xa inhibitor, rivaroxaban (Xarelto) [34]. [source, 2014]
For example, the recently completed XAMOS (Xarelto in the prophylaxis of post-surgical venous thromboembolism after elective Major Orthopaedic Surgery of hip or knee) study21 was a noninterventional study in which the use of rivaroxaban in routine practice for the prevention of venous thromboembolism after elective hip or knee replacement was evaluated, although local standard of care was included as a comparator. [source, 2014]
Three molecules are currently available in the clinical setting: dabigatran etexilate (Pradaxa, Boehringer-Ingelheim Pharma GmBH, Ingelheim am Rhein, Germany): 75 mg, 110 mg, and 220 mg capsules, rivaroxaban (Xarelto, Johnson and Johnson/Bayer HealthCare AG, Leverkusen, Germany): 2.5 mg, 10 mg, 15 mg, and 20 mg tablets, and apixaban (Eliquis, Bristol Myers Squibb/Pfizer, Bristol Myers Squibb House, Uxbridge, United Kingdom): 2.5 mg and 5 mg tablets. [source, 2014]
The drug Xarelto (rivaroxaban) is indicated for deep vein thrombosis, but it is unclear if the recurrent tonsillitis is associated with the medicine. [source, 2014]
With the arrival of a new generation of oral anticoagulants—direct factor Xa inhibitors rivaroxaban (Xarelto) and Dabigatran (Pradaxa) and the direct thrombin inhibitor apixaban (Eliquis)—many of these burdens on both the patient and the healthcare system have been alleviated. [source, 2014]
The European prescribing information states that “in patients with moderate renal impairment (creatinine clearance 30–49 mL/min) concomitantly receiving other medicinal products which increase rivaroxaban plasma concentrations, Xarelto [rivaroxaban] is to be used with caution”.2 [source, 2014]
Dabigatran etexilate (Pradaxa, Boehringer Ingelheim) [8], rivaroxaban (Xarelto, Bayer HealthCare) [9], and apixaban (Eliquis, Bristol Myers Squibb) [10] are new oral anticoagulants (NOAC) available in Europe and other countries. [source, 2013]
For all patients, rivaroxaban (Xarelto, 10 mg/day, p.o.) was administered for 5 weeks after surgery. [source, 2013]